All the news Showing 10 of 15 articles from: European policyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources DAAs safe and effective in elderly people with HCV Michael Carter / 05 September 2018 Treatment with direct-acting antivirals (DAAs) is safe and effective in elderly people with hepatitis C virus (HCV) infection, according to German research published in Drugs & Aging. Elderly people (aged 70 years ... New EACS treatment guidelines Keith Alcorn / 31 October 2017 Everyone with HIV and hepatitis C virus (HCV) co-infection should receive direct-acting antiviral treatment for hepatitis C and should receive the same treatment for hepatitis C as people with hepatitis C monoinfection, ... European Medicines Agency warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C EMA / 07 December 2016 Fast Advance in Hepatitis C Care Prompts EMA to Revise Clinical Trial Guideline Regulatory Affairs Professionals Society / 17 July 2016 Petition to European Parliament: Access to Hepatitis C Prevention, Testing, Treatment and Care for People Who Use Drugs Change.org / 27 October 2014 Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C Fierce PharmaMarketing / 11 September 2014 European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection Bristol-Myers Squibb / 27 August 2014 OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection Reuters / 16 May 2014 ELPA's Manifesto on policy measures against chronic liver disease ELPA / 24 March 2014 Hepatitis C: Setting Standards in a Journey towards the Eradication of Infection and Disease as a Serious Health Issue in the EU ELPA / 24 March 2014 ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive